Robert Lechleider
Net worth: 2 M $ as of 31/08/2026
Net worth: 2 M $ as of 31/08/2026
Robert Lechleider is currently Chief Medical Officer at Immunome, Inc. since 2023.
Formerly, Dr. Lechleider was Chief Medical Officer at OncoResponse, Inc. from 2020 to 2023 and Senior Vice President-Clinical Development at Seagen, Inc. from 2016 to 2020.
Education includes undergraduate studies at Princeton University and a doctorate from the University of Illinois College of Medicine.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
IMMUNOME, INC. 0.06% | 23/07/2026 | 69,805 ( 0.06% ) | 2 M $ | 31/08/2026 |
| Companies | Position | Start |
|---|---|---|
| IMMUNOME, INC. | Chief Tech/Sci/R&D Officer | 19/10/2023 |
| Companies | Position | End |
|---|---|---|
OncoResponse, Inc.
OncoResponse, Inc. Pharmaceuticals: MajorHealth Technology Discovers cancer immunotherapies by interrogating the human immune system | Chief Tech/Sci/R&D Officer | 01/10/2023 |
| SEAGEN INC. | Chief Tech/Sci/R&D Officer | 01/04/2020 |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 5 |
|---|---|
Seagen, Inc.
Seagen, Inc. Pharmaceuticals: MajorHealth Technology Discovers, develops and commercializes cancer medicines | Health Technology |
Immunome, Inc.
Immunome, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company which discovers, develops and commercializes antibody therapeutics | Health Technology |
Princeton University
Princeton University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Illinois College of Medicine
University of Illinois College of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
OncoResponse, Inc.
OncoResponse, Inc. Pharmaceuticals: MajorHealth Technology Discovers cancer immunotherapies by interrogating the human immune system | Health Technology |
Select your edition
All financial news and data tailored to specific country editions